BNP (B-type Natriuretic Peptide) vs MGF (Mechano Growth Factor)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | MGF (Mechano Growth Factor) |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 400 mcg–1.2 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 1–4 weeks | 4–6 weeks |
| Route | subcutaneous | intramuscular |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), MGF (Mechano Growth Factor) are both commonly used for:
Key Differences
Unique to MGF (Mechano Growth Factor):
Which Has Stronger Evidence?
| Goal | BNP (B-type Natriuretic Peptide) | MGF (Mechano Growth Factor) |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
MGF (Mechano Growth Factor)
- The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.
Acta biochimica et biophysica Sinica, 2023
- Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia.
International immunopharmacology, 2021
- Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity.
Experimental neurology, 2020
Ready to Learn More?
Looking for trusted sources?